Millipore Sigma Vibrant Logo

IM37 Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4)

This Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) is validated for use in Frozen Sections, Immunoblotting, Paraffin Sections for the detection of MMP-9 (Ab-3).

Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9

View Products on Sigmaaldrich.com
IM37
가격 및 재고 조회

개요

Replacement Information

주요 사양표

Species ReactivityHostAntibody Type
Gp, H, Rb, RMMonoclonal Antibody

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
IM37-100UGCN
재고 정보 검색...
—
현재 재고 없음 현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      		 Plastic ampoule 100 μg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      —
      가격 문의
      		 —
      Description
      OverviewRecognizes the ~92 kDa latent and the ~83 kDa active forms of MMP-9 in breast carcinoma tissue.
      Catalogue NumberIM37
      Brand Family Calbiochem®
      SynonymsAnti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9
      Application Data
      Detection of human MMP-9 by immunoblotting. Sample: Conditioned medium of human fibrosarcoma HT1080 cells. Primary antibody: Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37) (2 µg/ml). Detection: chemiluminescence.
      References
      ReferencesCottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Product Information
      DeclarationManufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
      Negative controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      Positive controlMMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting, Original Clone Okada, Y., et al. 1992. J. Biol. Chem. 267, 21712. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69. Tsuchiya, Y., et al. 1994. Int. J. Cancer 56, 46.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Paraffin Sections (see application references)
      Application CommentsThis antibody does not react with MMP-1, MMP-2, MMP-3 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena synthetic peptide corresponding to amino acids 626-644 of human MMP-9
      ImmunogenHuman
      Clone56-2A4
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Guinea Pig
      • Human
      • Rabbit
      • Rat
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      IM37-100UGCN 07790788053796

      Documentation

      Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) Certificates of Analysis

      TitleLot Number
      IM37

      References

      참고문헌 보기
      Cottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision22-February-2011 RFH
      SynonymsAnti-Gelatinase B, Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9
      ApplicationFrozen Sections (see application references)
      Immunoblotting (1 µg/ml)
      Paraffin Sections (see application references)
      Application Data
      Detection of human MMP-9 by immunoblotting. Sample: Conditioned medium of human fibrosarcoma HT1080 cells. Primary antibody: Anti-MMP-9 (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37) (2 µg/ml). Detection: chemiluminescence.
      DescriptionPurified mouse monoclonal antibody (see application references). Recognizes both the ~92 kDa latent and the ~83 kDa active forms of MMP-9.
      BackgroundMatrix metalloproteinases (MMP's) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMP's share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N-terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis. MMP-9 (Gelatinase B, 92 kDa gelatinase/type IV collagenase) is secreted as a 92 kDa zymogen which is proteolytically processed to the 83 kDa active form. MMP-9 shows substrate specificity toward type IV and V collagens, gelatin and elastin.
      HostMouse
      Immunogen speciesHuman
      Immunogena synthetic peptide corresponding to amino acids 626-644 of human MMP-9
      Clone56-2A4
      IsotypeIgG₁
      Speciesnot bovine, guinea pig, not hamster, human, not mouse, rabbit, rat
      Positive controlMMP-9 protein (Cat. Nos. PF024 or PF038) or breast carcinoma tissue
      Negative controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThis antibody does not react with MMP-1, MMP-2, MMP-3 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesCottam, D.W. and Rees, R.C. 1993. Intl. J. Oncol. 2, 861.
      Stetler-Stevenson, W.G., et al. 1993. FASEB J. 7, 1434.
      Okada, Y., et al., 1992. J. Biol. Chem. 267, 21712.
      Woessner, J.F. 1991. FASEB J. 5, 2145.
      Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1, 99.
      Application referencesImmunoblotting, Original Clone Okada, Y., et al. 1992. J. Biol. Chem. 267, 21712. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69. Tsuchiya, Y., et al. 1994. Int. J. Cancer 56, 46.